John Parkinson

Learn more about an investigational antibiotic; a new series on the RSV pipeline and recently approved products; a review of an older antibiotic for a specific STI treatment; and a patient advocate's experience with C diff.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

In preclinical studies, the antimicrobial, clovibactin, was shown to have susceptibility against a broad spectrum of pathogens and also worked against a specific bacteria in 2 animal studies.

If approved, the investigational vaccine would be available to people 18 years and older.

This is part of an occasional series with members of the Peggy Lillis Foundation. Here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.

This is the first in an occasional series with members of the Peggy Lillis Foundation. Here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.

In this week's biggest stories, masks are seeing a small resurgence; expanding HCV screening for all persons with HIV; Pfizer's maternal vaccine gets FDA approved; and how a risk-based screening for multidrug-resistant gut microbes could improve accuracy and timeliness of empiric antibiotic treatment

Alyssa Dykstra is experiencing a drastic increase in paying for her medication for autoimmune arthritis. Insurers are utilizing a loophole provided by the federal government to allow them to disallow coupons, thus raising prescription costs for patients.

The federal agency says everyone should immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops–Eye Repair due to bacterial contamination, fungal contamination, or both.

Masking to reduce COVID-19 transmission risk is required at a few colleges and one major movie studio.

Novavax updates its COVID-19 vaccine, locally acquired malaria is reported in Maryland, deadly listeria outbreak is linked to milkshakes, and vibriosis in the northeast.

Poll conducted by University of Michigan had a majority of people wanting to know more about it.

This week: the FDA accepts NDA for investigational antibiotic; mRNA COVID-19 vaccines update protections; counseling families on nirsevimab; and how antibiotic actions on gut microbes of patients might affect the microbiome of housemates.

The strain, Eris (EG5), is from the Omicron lineage, and the expectations are the newest vaccines will protect against it, and other variants from the same family.

With the FDA approval of nirsevimab-alip (Beyfortus), which is indicated for prevention of respiratory syncytial virus (RSV) in infants, clinicians will need to have important conversations with families around this monoclonal antibody, beginning this fall.

The Prescription Drug User Fee Act (PDUFA) action date is scheduled for the first quarter of 2024.

The agency says additional time is needed to decide upon a phase 4 program.

This week's news included managing infants with RSV, how COVID-19 surveillance has evolved, and looking at changing criteria for initial and sustained response to antibiotic treatment for C diff.

A clinician offers a glimpse of what it is like to treat infants with respiratory syncytial virus (RSV). And with the recent FDA approval of nirsevimab, how that will likely benefit families and the youngest population.

From news about RSV to vaccines to an investigational hepatitis therapy, this week's Infectious Disease Update has something for everyone.

A new study confirms this form of surveillance to collect metrics for SARS-CoV-2 to understand infection prevalence on a bigger scale.

The federal agency’s Advisory Committee on Immunization Practices (ACIP) also added the recently approved therapeutic to the Vaccines for Children program.

A new study demonstrated Moderna having a greater efficacy and slightly less adverse event profile in this patient population vs the Pfizer-BioNTech vaccine.

The twice-yearly injectable shown to be beneficial in conjunction with an optimized background regimen.

A new study being presented at the ongoing IAS conference showed that people with HIV found the injectable therapy, Cabotegravir plus long-acting Rilpivirine (Cabenuva) is more conducive to today’s lifestyles, reduced stigma, and improved adherence.

New study demonstrates benefit of adhering to treatment regimen and also calls for simplifying viral testing in other parts of the world where updated panels technology may not be available.

Coverage this week included how COVID-19 vaccines in patients with cancer fared; analysis of non-COVID-19 adult vaccines; a company is developing a platform to enable engineering of the first recombinant human polyclonal antibody therapies with the goal of creating a functional cure for hepatitis b; and how a hospital modified testing for C difficile.

New report published this week shows the decrease over the last 2 reportable years.

This conference is addressing antimicrobial resistance (AMR) from different perspectives and look at strategies to reduce this global health problem.

The Gates Medical Research Institute (MRI) is conducting a study looking at the effect of bifidobacterium longum subspecies infantis (B infantis) as a supplement.